STAAR Surgical Company is a developer, producer, implanter and marketer of implantable lenses for the eye,

According to the Plaintiff's law firm press release, Staar Surgical Company has recently emphasized its revenue, sales growth, and market share in the Chinese market. STAAR attributed its success to its strategic partnerships, including with its customer AIER, a Chinese ophthalmology hospital group.

The Complaint alleges that during the Class Period, Defendants misrepresented and/or failed to disclose to investors that the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants’ public statements were materially false and misleading at all relevant times.

On September 11, 2020, the Court issued an Order consolidating actions. On October 29, the Court issued an Order consolidating actions and appointing Lead Plaintiff and Counsel.

Lead Plaintiff voluntarily dismissed this case on January 15, 2021.